JP2023532675A5 - - Google Patents
Info
- Publication number
- JP2023532675A5 JP2023532675A5 JP2022580178A JP2022580178A JP2023532675A5 JP 2023532675 A5 JP2023532675 A5 JP 2023532675A5 JP 2022580178 A JP2022580178 A JP 2022580178A JP 2022580178 A JP2022580178 A JP 2022580178A JP 2023532675 A5 JP2023532675 A5 JP 2023532675A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- combination
- use according
- compound
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20182364.8 | 2020-06-25 | ||
| EP20182364 | 2020-06-25 | ||
| EP21167277 | 2021-04-07 | ||
| EP21167277.9 | 2021-04-07 | ||
| PCT/EP2021/067346 WO2021260109A1 (en) | 2020-06-25 | 2021-06-24 | A COMBINATION OF A CBP/p300 BROMODOMAIN INHIBITOR AND AN EGFR INHIBITOR FOR USE IN TREATING EGFR-MUTANT NSCLC |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023532675A JP2023532675A (ja) | 2023-07-31 |
| JP2023532675A5 true JP2023532675A5 (cg-RX-API-DMAC7.html) | 2024-06-19 |
Family
ID=76502741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580178A Pending JP2023532675A (ja) | 2020-06-25 | 2021-06-24 | EGFR突然変異NSCLCの治療に使用するための、CBP/p300ブロモドメイン阻害剤およびEGFR阻害剤の組合せ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230255966A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4171556A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023532675A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230028512A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115701996B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021298153A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022025911A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183982A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299438A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022016496A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021260109A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022006394A2 (pt) | 2019-10-02 | 2022-07-26 | Tolremo Therapeutics Ag | Derivados heterocíclicos, composições farmacêuticas e seu uso no tratamento ou melhora do câncer |
| WO2021260110A1 (en) | 2020-06-25 | 2021-12-30 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease |
| AU2021298154A1 (en) | 2020-06-25 | 2023-02-23 | Tolremo Therapeutics Ag | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer |
| CA3212085C (en) | 2021-04-07 | 2025-02-11 | Tolremo Therapeutics Ag | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR RELIEF OF CANCER |
| CN120359030A (zh) * | 2022-12-15 | 2025-07-22 | 冠科美博有限公司 | 使用c-MET抑制剂治疗对EGFR TKI具有耐药性的癌症 |
| PL449237A1 (pl) * | 2024-07-15 | 2026-01-19 | Uniwersytet Łódzki | Inhibitor acetylotransferaz do zastosowania w leczeniu niedrobnokomórkowego raka płuc oraz potrójnie negatywnego nowotworu piersi opornego na paklitaksel |
| WO2026128761A1 (en) | 2024-12-11 | 2026-06-18 | Nexo Therapeutics, Inc. | Covalent p300 inhibitor compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9005670B2 (en) | 2010-01-05 | 2015-04-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| WO2013148114A1 (en) * | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | P300/cbp inhibitors and methods of use |
| CN105979958A (zh) * | 2013-10-11 | 2016-09-28 | 基因泰克公司 | Cbp/ep300布罗莫结构域抑制剂用于癌症免疫疗法的用途 |
| WO2016123054A2 (en) * | 2015-01-26 | 2016-08-04 | The University Of North Carolina At Chapel Hill | Kinase drug combinations and methods of use thereof |
| CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| JP2019524740A (ja) | 2016-07-25 | 2019-09-05 | エピザイム インコーポレイテッド | Crebbp関連癌の治療法 |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2018195450A1 (en) * | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| BR112019025346A2 (pt) * | 2017-05-30 | 2020-06-30 | Deciphera Pharmaceuticals, Inc. | uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-naftiridin-3-il]-2-fluorofenil]-3-fenilureia e análogos para o tratamento de cânceres associados a anormalidades genéticas no receptor alfa do fator de crescimento derivado de plaquetas |
| EP3661519A1 (en) * | 2017-08-03 | 2020-06-10 | Novartis AG | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor |
| SG11201913249SA (en) * | 2017-08-03 | 2020-02-27 | Novartis Ag | Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor |
| GB201806320D0 (en) | 2018-04-18 | 2018-05-30 | Cellcentric Ltd | Process |
| IL279734B2 (en) | 2018-06-29 | 2024-11-01 | Forma Therapeutics Inc | Inhibiting creb binding protein (cbp) |
| CN110652514A (zh) * | 2018-06-29 | 2020-01-07 | 上海翰森生物医药科技有限公司 | 第三代egfr抑制剂的制药用途 |
| US12290521B2 (en) * | 2018-07-25 | 2025-05-06 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating BET inhibitor-resistant cancers |
-
2021
- 2021-06-24 EP EP21733158.6A patent/EP4171556A1/en active Pending
- 2021-06-24 JP JP2022580178A patent/JP2023532675A/ja active Pending
- 2021-06-24 CN CN202180044594.4A patent/CN115701996B/zh active Active
- 2021-06-24 BR BR112022025911A patent/BR112022025911A2/pt unknown
- 2021-06-24 KR KR1020237002916A patent/KR20230028512A/ko active Pending
- 2021-06-24 IL IL299438A patent/IL299438A/en unknown
- 2021-06-24 CA CA3183982A patent/CA3183982A1/en active Pending
- 2021-06-24 US US18/012,278 patent/US20230255966A1/en active Pending
- 2021-06-24 AU AU2021298153A patent/AU2021298153A1/en active Pending
- 2021-06-24 WO PCT/EP2021/067346 patent/WO2021260109A1/en not_active Ceased
- 2021-06-24 MX MX2022016496A patent/MX2022016496A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024133475A5 (cg-RX-API-DMAC7.html) | ||
| TW202038957A (zh) | 抗體-藥物結合物與激酶抑制劑之組合 | |
| CN101678029A (zh) | 基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途 | |
| JP2020504742A5 (cg-RX-API-DMAC7.html) | ||
| JP2020533298A (ja) | Her誘発性薬剤耐性がんの治療又は予防のための化合物、組成物及び方法 | |
| JP2025038167A (ja) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 | |
| JP2018090566A5 (cg-RX-API-DMAC7.html) | ||
| RU2020108191A (ru) | Терапевтическая комбинация ингибитора тирозинкиназы egfr третьего поколения и ингибиторa циклин-d-киназы | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| CN102647986A (zh) | 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法 | |
| RU2020108192A (ru) | Терапевтическая комбинация ингибитора тирозинкиназы egfr третьего поколения и ингибитора raf | |
| CA2439440A1 (en) | Treatment of tuberous sclerosis associated neoplasms | |
| AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
| EP4615869A1 (en) | Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain | |
| EP4146217A1 (en) | Pharmaceutical combination comprising tno155 and nazartinib | |
| JP2023524789A5 (cg-RX-API-DMAC7.html) | ||
| ES2855075T3 (es) | Combinación de ceritinib con un inhibidor de EGFR | |
| RU2017143182A (ru) | Способы и композиции для ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы | |
| CN113543784A (zh) | 用于治疗或预防癌症的喹啉衍生物 | |
| RU2015124954A (ru) | Фармацевтические комбинации | |
| JP2007537184A (ja) | 抗血小板剤に対する耐性を治療するためのジピリダモールの使用 | |
| EP3458064A1 (en) | Anticancer combination therapy | |
| CA3113408A1 (en) | Cancer combination therapy using quinoline carboxamide derivative | |
| JP2024517477A5 (cg-RX-API-DMAC7.html) | ||
| KR20260073391A (ko) | Wee1 저해제와 pkmyt1 저해제의 조합 |